GlassScriptPhysician profile
Lilly Ma-Perez
NPI 1497139869
$4,531.66
in general payments reported to CMS, 2019-2025
24 companies · $859 in 2025
The $859 reported for 2025 was more than what 96% of Pediatrics (Nurse Practitioner) providers received nationally (typical 2025 total: $93.49).
See the full distribution for Pediatrics (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,176 · 2022: $1,198 · 2023: $629 · 2024: $669 · 2025: $859.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,157.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $738.47 | 2021-2024 | Adzenys Xr-Odt |
| Corium, LLC | $707.52 | 2022-2025 | Azstarys |
| Neurelis, INC. | $505.72 | 2021-2025 | Valtoco |
| Supernus Pharmaceuticals, INC. | $478.71 | 2021-2025 | Qelbree, Qelbree |
| Tris Pharma INC | $471.40 | 2021-2025 | Dyanavel Xr, Onyda Xr |
| Ucb, INC. | $385.47 | 2021-2025 | Briviact, Nayzilam, Fintepla |
| Ironshore Pharmaceuticals INC. | $372.54 | 2022-2024 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $215.29 | 2021-2022 | |
| Abbvie INC. | $110.41 | 2021-2025 | |
| Vertical Pharmaceuticals, LLC | $96.99 | 2024-2025 | Relexxii |
| Adlon Therapeutics L.P. | $90.34 | 2021 | |
| Collegium Pharmaceutical, INC. | $57.03 | 2025 | Jornay Pm |
| Zogenix INC. | $44.68 | 2021 | |
| Azurity Pharmaceuticals, INC. | $39.04 | 2023-2025 | Zonisade, Eprontia |
| Avion Pharmaceuticals | $34.27 | 2023-2024 | Methylphenidate Hydrochloride, Relexxii |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $29.28 | 2021-2022 | |
| Cognoa, INC. | $28.48 | 2021 | |
| Ptc Therapeutics, INC. | $25.24 | 2023 | Emflaza |
| Biocodex, INC. | $22.98 | 2025 | |
| Jazz Pharmaceuticals INC. | $22.72 | 2021 | |
| Arbor Pharmaceuticals, INC. | $16.91 | 2022 | |
| Sunovion Pharmaceuticals INC. | $16.40 | 2022 | |
| Metacel Pharmaceuticals LLC | $16.34 | 2024 | Ozobax |
| Aytu Biopharma, INC. | $5.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lilly Ma-Perez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.